Slide 1: Exchange cover letter for investor presentation
Laurus Labs Limited Corporate Office 2"d Floor, Serene Chambers, Road No. 7 Banjara Hills, Hyderabad - 50003~. Telangana, India T +91 ~0 3980~333 I 23~2 0500 I 501 LAURUS Labs F +91 ~0 3980 ~320 Knowledge . Innovation . Excellence January 30, 2020 To To The Corporate Relations Department The Listing
Slide 2: Laurus Labs Limited Q3 & 9M FY20 Investor Presentation
LAURUS LABS LIMITED Q3 & 9M FY20 INVESTOR PRESENTATION January 30, 2020 BSE: 540222 NSE : LAURUSLABS
Slide 3: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 4: Business Snapshot
Business Snapshot - API -FDF Overview • Development, manufacture and sale • Developing and manufacturing • Contract development and • Sale and manufacture of of APIs and Advanced Intermediates oral solid formulations for LMIC, manufacturing services for specialty ingredients for use in • Leadership
Slide 5: Growth Verticals – Diversified Pharma Company
Growth Verticals – Diversified Pharma Company • Leveraging API Synergies for Forward Integration • Targeting various high growth markets like LMIC, US, Canada, & Europe • Therapeutic Focus Areas remains on key segments of ARV, CVS, CNS, PPI & Anti Formulations Diabetic • Supplied additional demand i
Slide 6: Formulations Business
Formulations Business
Slide 7: Formulations Strategy – Emerging Markets
Formulations Strategy – Emerging Markets Growth Levers • ARV Tender business from LMIC remains the forefront of our Formulations Strategy. Overview • Formulation Filings are deeply backward Integrated giving further cost advantage compared to peers Participation via – Global Fund tenders, PEPFAR, WH
Slide 8: Formulations Strategy – Developed Markets
Formulations Strategy – Developed Markets Current Filings Status Current Approval Status Therapy US ANDA Europe Canada Therapy US ANDA Europe Canada ARV 14 4 5 Final Approval 5 5 5 Anti- Diabetic 3 1 1 Tentative CVS 2 - - Approval 3 - - CNS 1 1 1 Total 8 5 5 Others 4 - 2 Total 24 6 9 North America •
Slide 9: Synthesis Business
Synthesis Business
Slide 10: Synthesis (CDMO) Business Strategy
Synthesis (CDMO) Business Strategy 2552 1810 1541 1075 761 FY 16 FY 17 FY 18 FY19 9M FY20 Synthesis Revenue (INR Mn) OVERVIEW • State-of-the-art cGMP facilities to manufacture NCEs and Intermediates • Integrated projects from Pre Clinical to Commercial stages • Working with Large Global Innovator Ph
Slide 11: Generic API Business
Generic API Business
Slide 12: Generic APIs Strategy
Generic APIs Strategy • Oncology - Growth in the segment will be led by new launches and increase in market share of existing products • Strengthening Global Leadership in current products • Other API - Huge growth opportunity on offer with global supply disruptions in the market • Focusing on key t
Slide 13: Infrastructure & R&D
Infrastructure & R&D
Slide 14: Manufacturing Facilities at Parawada, Vizag
Manufacturing Facilities at Parawada, Vizag Unit-I • Located at Jawaharlal Nehru Pharma City, Vishakhapatnam, India. • API manufacturing facility and includes capacity for ingredients, synthesis and contract manufacturing. • Commenced operations in 2007. • 323 reactors with 1,196 Kilo Liters capacit
Slide 15: Manufacturing Facilities at Achutapuram, Vizag
Manufacturing Facilities at Achutapuram, Vizag • Located at APIIC, Achutapuram, Visakhapatnam, India. (SEZ) Unit-II • FDF and API manufacturing facility • Commenced operations in 2017. • FDF - capacity of 5 bn tablets/capsules per year. Capacity expansion initiated and will be operational by Septemb
Slide 16: Strong R&D Capabilities
Strong R&D Capabilities R&D Centre - Hyd 1,659 1,338 1,135 1,204 853 7.4% 7.1% 5.6% 4.8% 6.0% FY16 FY17 FY18 FY 19 9M FY 20 R&D Spend % of Revenue 60+ 59 256 24 750+ 50+ Products Filed Patents ANDAs/ NDAs Scientists PhDs commercialized DMFs filed since inception 5&3 107 Patents Final & Tentative gra
Slide 17: Quality Focus & Regulatory Audits
Quality Focus & Regulatory Audits Laurus’ Philosophy “One Quality Standard for all markets” Regular Inspection at different manufacturing units 2019 USFDA, ANVISA, KFDA, JAZMP – Slovenia We maintain consistent quality, efficiency and product 2018 USFDA, JAZMP - Slovenia safety. 2017 WHO, USFDA, EU (
Slide 18: Financial Performance
Financial Performance
Slide 19: Drivers of Revenue – Division-wise revenue breakup
Drivers of Revenue – Division-wise revenue breakup 4% 2% Total Revenue showed a robust growth of 38% for the quarter (Y-o-Y) & 2% 2% 20% for 9m (Y-o-Y) 23% 10% 10% 28% 7% Generic API 40% 9% 4% 9% • ARV Segment revenue declined mainly due to lower off-take 3% 11% 8% 5% of Efavirenz and FTC API’s du
Slide 20: Performance Highlights - Abridged Profit & Loss statement
Performance Highlights - Abridged Profit & Loss statement Growth Growth % Growth % % (Q3 FY20 Particulars (Rs. mn) Q3 FY20 Q3 FY 19 (Q3 FY20 Vs. Q2 FY 20 9M FY20 9M FY19 (9M FY20 Vs. Q3 FY 19) Vs. Q2 FY 20) 9M FY19) Revenue from Operations (Net) 7,296 5,295 37.8% 7,124 2.4% 19,926 16,568 20.3% EBITD
Slide 21: Snapshot of Return Ratios
Snapshot of Return Ratios Pre Tax Return on Capital Return on Equity(2) (%) Total Debt/Equity Ratio (x) Employed(1) (%) 16.5% 16.5% 17.0% 17.4% 1.2x 1.1x 14.5% 13.7% 12.7% 11.6% 11.9% 11.9% 0.7x 0.7x 0.7x 8.2% 0.6x 6.2% FY15 FY16 FY17 FY 18 FY 19 FY 20 FY15 FY16 FY17 FY 18 FY 19 FY 20 FY15 FY16 FY17
Slide 22: Key Milestones
Key Milestones • Investment of INR 3000 mn by • Investment of INR Warburg Pincus • Crossed INR 20 billion of revenue 600 mn by FIL • Incorporated First • Commenced commercial operations • Set up the R&D Capital Subsidiary in USA. • Successfully listed on BSE &NSE from Unit 4 Centre at IKP, Managemen
Slide 23: Management Team
Management Team Mr. Tom Versosky Mr. Chandrakanth Chereddi President FDF North America ED & Head, Generics FDF & Strategy Dr. Prafulla Kumar Nandi SVP, Global Regulatory Affairs Mr. Ravi kumar V V Mr. G Venkateshwar Reddy (Formulations) ED &CFO AVP – Legal & Secretarial Dr. Satyanarayana Chava Found
Slide 24: Corporate Governance
Corporate Governance Executive Directors Name Background Dr Satyanarayana Chava Whole-time Director, Founder and Chief Executive Officer Ravi Kumar V V Whole-time Director and CFO Chandrakanth Chereddi Whole-time Director and Head of Generic FDF and Strategy Dr Lakshmana Rao C V Whole-time D
Slide 25: Ownership Structure
Ownership Structure Corporate Structure Laurus Labs Limited India Laurus Synthesis Laurus Holdings All are 100% Sriam Labs Pvt Ltd. Inc. Ltd. Subsidiaries India USA UK Laurus Generics Laurus Generics Inc. GmbH. USA Germany Shareholding pattern * 32.6% 4.9% 10.5% 1.3% 0.5% 19.6% 5.7% 24.9% Promoter F
Slide 26: Awards 2019
Awards 2019 PORTER PRIZE 2019 NATIONAL SAFETY PHARMAEXCIL Laurus Labs won the prestigious Porter Prize 2019. The AWARD AWARD eponymous award was presented to Dr. Satyanarayana Chava, Founder & CEO, Laurus Labs, by Dr. Bibek Debroy, Laurus Labs, Unit 1 & Unit 3 won the Laurus Labs won the Pharmexcil
Slide 27: Fortune 500, Great Place To Work recognition
Laurus Labs is a Fortune 500 Company, Great Place To Work and one of the India’s Best Workplace in 2019 Laurus Labs is certified as Laurus Labs is recognized as Laurus Labs continues to be in the one of the Best Work Places in Fortune 500 Companies List in India “Great Place to Work” for the second
Slide 28: Results Conference Call
Results Conference Call Results conference call on Friday January 31, 2020 at 11:00 AM IST Details of the conference call are as follows: Timing 11:00 AM IST on Friday, January 31, 2020 Conference dial-in Universal Dial-In +91 22 6280 1214 India Local access Number +91 7045671221 Available all over
Slide 29: Contact us
Contact us About Laurus Labs Ltd. Laurus Labs is a leading research driven Pharmaceutical manufacturing Company in India. We have grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma and Gastroenterology .We are thri
Slide 30: Thank You
Thank You